NCT00442312

Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy

An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 43 (planned)
• Sponsor: Genovate Biotechnology Co., Ltd., · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and safety of Combigan ophthalmic solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension. Hypothesis: 1. Combigan Ophthalmic Solution provides addition IOP loweringwhen combined with Latanoprost. 2. The treatment with Combigan Ophthalmic Solution has an acceptable safety profile, as measured by ocular and systemic safety parameters.

Detailed description

The purpose of this study is to comparethe efficacy and safety Ophthalmic Solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension. The study will be open label, prospective, multi-centered where patients will be swiched from Latanoprostmonotherapy to a combination therapy of Latanoprost with Combigan Ophthalmic Solution.

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	Combigan Ophthalmic Solutiom

Timeline

• Start date: 2006-05-01
• Completion: 2006-11-01
• First posted: 2007-03-01
• Last updated: 2007-03-01

Locations

1 site across 1 country: Taiwan